SEEK is a drug-discovery group that uses a pioneering scientific and commercially-driven approach to create breakthrough medicines which address major diseases in order to radically improve human health. 5 th August 2011

Business Model SEEK is a privately owned biotech company led by Mr Gregory Stoloff (a seasoned financing and investment professional and scientist) and Dr Robin Bannister (a proven product discovery professional and entrepreneur) SEEK’s business strategy is to develop its assets internally to complete proof of principle to effectively lower the risk profile for future investors. These businesses then progress to independent management with dedicated and focused leadership. SEEK has successfully done this with its first ventures Infirst Healthcare and Care Oncology Clinic SEEK is now offering its next two business opportunities for investment

Vaccine Platform lead- Universal Influenza vaccine The lead Programme Flu-v a universal influenza vaccine and is among the most advanced universal vaccines in the world The revealed ineffectiveness of antiviral medication and the only partial effectiveness of annual vaccines and exposure to potential pandemic strains make the advent of this universal vaccine most timely Flu-v has demonstrated protection against all forms of influenza including A,B and pandemic strains and has completed Phase II proof of principle and is under collaboration with the NIH Investment sought is £5M to complete Phase II and provide investor exit and licensing. with the balance of funds most likely being provided by NIH/BARDA/EU

Universal FLU-v: Completed Initial Phase II Collaboration with NIH on FLU-v, for Phase IIb European grant for FLU-v, for Phase IIb study to identify immunogenicity Fast track Market Authorisation Granted patents in major territories HIV-v: Investment pending liaison with the NIH Fast track to Market Authorisation Granted patents in major territories Secondary products: Hep B, Hep C, Rotavirus, Chagas, Mosquito Diseases (All Pre- Clinical) Vaccine Platform- Lead Products

Sharing Knowledge Enhancing Quality DDL Optimised metabolic medicines in cancer Care Oncology Clinic

DDL Optimal use of metabolic medicines in cancer Care Oncology Clinic was founded in 2013 and its objective was to provide benefit to metastatic cancer patients through off label treatment with metabolic medicines having a long history of use in cancer alongside standard of care Since founding over 500 patients have been treated at COC and preliminary observation, support the historical invitro, invivo, human clinical and epidemiology data that underpin their use. This extensive knowledge has allowed DDL to identify the best and optimal situations to truncate and ensure the successful repurposing of these drugs

DDL Optimisation of metabolic medicines in cancer The existing drugs although effective have not been optimised for either dose or delivery to tumours and cancer patients SEEKs proprietary technology, which has already been successfully developed and registered for enhancing drugs by Infirst Healthcare and is now employed to drive benefit in cancer patients in DDL Application as adjunctive care across all cancers and standard of care supports wide adoption and underpins DDL as a commercially attractive investment with products that are affordable to payers. SEEK is now starting to progressing DDL under independent financing and leadership and is looking for partners.